Tumor Necrosis Factor

Ixekizumab Benefits Patients With Treatment-Resistant Psoriatic Arthritis

Ixekizumab Benefits Patients With Treatment-Resistant Psoriatic Arthritis

By

Ixekizumab was found to benefit patients with psoriatic arthritis showing poor response to conventional treatment when administered over a 2- or 4-week period.

Etanercept May Increase Risk of Anterior Uveitis in Ankylosing Spondylitis

Etanercept May Increase Risk of Anterior Uveitis in Ankylosing Spondylitis

By

Researchers examined whether different TNF inhibitors were associated with different rates of anterior uveitis in patients with ankylosing spondylitis undergoing treatment with adalimumab, etanercept, or infliximab.

Tocilizumab Highly Effective in Refractory Juvenile Idiopathic Arthritis-associated Uveitis

Tocilizumab Highly Effective in Refractory Juvenile Idiopathic Arthritis-associated Uveitis

Tocilizumab therapy showed rapid improvement in ocular parameters for uveitis in juvenile idiopathic arthritis patients.

Sirukumab Rapidly Improves Rheumatoid Arthritis Symptoms in Difficult-to-Treat Patients

Sirukumab Rapidly Improves Rheumatoid Arthritis Symptoms in Difficult-to-Treat Patients

By

Study examined patients with active rheumatoid arthritis who failed to derive benefit from or were intolerant to TNF-inhibitor therapy.

High-dose Steroids Increase Serious Infection Risk in Pregnant Women With Inflammatory Conditions

High-dose Steroids Increase Serious Infection Risk in Pregnant Women With Inflammatory Conditions

By

An observational cohort study of 4961 women with completed pregnancies and a recorded diagnosis of systemic inflammatory conditions.

Secukinumab Improves Symptoms in TNF Inhibitor-Refractory Rheumatoid Arthritis

Secukinumab Improves Symptoms in TNF Inhibitor-Refractory Rheumatoid Arthritis

By

A phase 3, double-blind, randomized placebo-controlled study was conducted in 551 patients with active rheumatoid arthritis who received secukinumab, abatacept, or placebo.

Minimal Amount of TNF Inhibitor Transfers to Breast Milk, Study Finds

Minimal Amount of TNF Inhibitor Transfers to Breast Milk, Study Finds

By

Study evaluated breast milk samples from 17 lactating mothers diagnosed with rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis.

Etanercept for Rheumatoid Arthritis Has Lower Infection Risk

Etanercept for Rheumatoid Arthritis Has Lower Infection Risk

By

The TNF inhibitor shows lower risk for infections and tuberculosis, according to a recent study.

ASAS/EULAR Revise Axial Spondyloarthritis Management Recommendations

ASAS/EULAR Revise Axial Spondyloarthritis Management Recommendations

By

Collaborative document provides guidance on non-pharmacological and pharmacological management in patients with axial spondyloarthritis.

Brief Exercise Sessions Can Reduce Systemic Inflammation

Brief Exercise Sessions Can Reduce Systemic Inflammation

By

Small study shows 20 minutes on a treadmill can decrease immune cells tied to inflammation.

Early Biologic Therapy for Rheumatoid Arthritis Improves Ability to Work

Early Biologic Therapy for Rheumatoid Arthritis Improves Ability to Work

By

The likelihood of regaining ability to work was studied in patients with rheumatoid arthritis who initiated anti-tumor necrosis factor therapy within 5 years.

Comparable Pregnancy Outcomes With TNFi Use in Immune-Mediated Disease

Comparable Pregnancy Outcomes With TNFi Use in Immune-Mediated Disease

By

Patients taking TNF-α inhibitors(TNFis) with immune mediated disease had comparable pregnancy-related outcomes to those not taking TNFis, but had significantly increased risks for adverse outcomes compared with the general population

Is Age a Factor in Determining TNFi Discontinuation in RA?

Is Age a Factor in Determining TNFi Discontinuation in RA?

By

Identifying appropriate biologic DMARDs for elderly patients with RA is becoming increasingly important.

Quantifying Disease Flares After Discontinuing TNFis in Stable RA

Quantifying Disease Flares After Discontinuing TNFis in Stable RA

By

Patients randomized to discontinuing TNFis were at increased risk of experiencing a disease flare within 12 months.

Secukinumab Efficacy in TNFi-Naïve & Exposed PsA Patients Compared

Secukinumab Efficacy in TNFi-Naïve & Exposed PsA Patients Compared

By

Post-hoc analysis of the FUTURE-2 trial was performed to assess if there was a differential treatment responses to secukinumab in TNFi-exposed or naïve patients with active psoriatic arthritis.

Paradoxical Activation of TNF-Regulatory Functions by Adalimumab

Paradoxical Activation of TNF-Regulatory Functions by Adalimumab

Therapeutic anti-TNF antibodies, long thought to act primarily via blockade of proinflammatory soluble TNF, appear to also bind membrane-bound TNF supporting regulatory T-cell expansion suppressing further inflammation.

Efficacy of CZP+MTX in DMARD-Naïve Patients With Severe RA and Poor Prognostic Factors

Efficacy of CZP+MTX in DMARD-Naïve Patients With Severe RA and Poor Prognostic Factors

By

Dose-optimized MTX in combination with CZP resulted in more patients achieving sustained low disease activity as compared to placebo with dose-optimized MTX in DMARD-naïve early RA.

What Drug Should RA Patients Be Switched to After Tocilizumab Failure?

What Drug Should RA Patients Be Switched to After Tocilizumab Failure?

By

The proportion of patients who achieved low disease activity or remission was significantly higher in the TNFi group compared with the ABT group.

Systematic Review of Feasible Anti-TNF Tapering Strategies in AxSpA

Systematic Review of Feasible Anti-TNF Tapering Strategies in AxSpA

By

Tapering of anti-TNF therapy can facilitate sustained remission or lower disease activity in most patients with axial spondyloarthritis while ameliorating both risk for adverse events and treatment costs.

Head-To-Head Comparison of Tocilizumab, Abatacept, Rituximab After Non-TNFi Failure in RA

Head-To-Head Comparison of Tocilizumab, Abatacept, Rituximab After Non-TNFi Failure in RA

A subset of patients with RA fail to respond to tumor necrsis factor (TNF) inhibitor therapy. This study was conducted to evaluate the efficacy of tocilizumab, abatacept and rituximab in these patients.

MTX Dose Does Not Impact CZP Efficacy in RA

MTX Dose Does Not Impact CZP Efficacy in RA

By

Methotrexate (MTX) dosage does not impact the efficacy of certolizumab pegol (CZP) in patients with rheumatoid arthritis receiving combination therapy, suggesting that MTX dose modification is feasible without compromising efficacy.

TNF Inhibitors and Risk Factors for Fungal and Mycobacterial Infections

TNF Inhibitors and Risk Factors for Fungal and Mycobacterial Infections

By

The use of tumor necrosis factor (TNF) inhibitors is associated with an increased risk for a variety of serious infections because TNF-alpha plays a key role in macrophage and phagosome activation, monocyte differentiation into macrophages, and neutrophil recruitment.

USPSTF Draft Statement: Latent TB Screening For TNFi Users

USPSTF Draft Statement: Latent TB Screening For TNFi Users

By

The USPSTF concludes with moderate certainty a moderate net benefit in screening at-risk adults for latent tuberculosis infection (LTBI).

Results of Phase 3 Investigational Biologic DMARD for RA

Results of Phase 3 Investigational Biologic DMARD for RA

By

Regeneron and Sanofi announced their Phase 3 study for sarilumab has met its primary endpoint, demonstrating superiority over adalimumab in improving symptoms in patients with active rheumatoid arthritis (RA) at Week 24, in the SARIL-RA-MONARCH trials.

No Significant Increased Risk of Birth Defects in Offspring of Women on Anti-TNF Agents

No Significant Increased Risk of Birth Defects in Offspring of Women on Anti-TNF Agents

Women who received anti-TNF agents during pregnancy did not have a significantly higher risk of having children with birth defects.

TNF-Inhibition for Treatment of Arthritis Increases Risk of Multiple Sclerosis

TNF-Inhibition for Treatment of Arthritis Increases Risk of Multiple Sclerosis

By

There is an increased risk of MS with TNFi therapy, highest in men after the first two years of treatment. This increased risk of MS may be most pronounced and specific to certain cohorts of patients.

Increased Risk of Myocardial Infarction With Anti-TNF Biologics in RA

Increased Risk of Myocardial Infarction With Anti-TNF Biologics in RA

By

Research has identified that certain anti-TNF biologic drugs may confer an elevated risk of MI compared to other medications.

Cytokine Converter Cell Implants Offer a Translational Approach to Treating Psoriasis and Other Chronic  Immune Disorders

Cytokine Converter Cell Implants Offer a Translational Approach to Treating Psoriasis and Other Chronic Immune Disorders

By

Normal skin tissue morphology restored in psoriatic mice implanted with microencapsulated cytokine converter transgenic designer cells.

FDA Issues Advisory for Increased Risk of Lymphoma in Patients Treated With Golimumab

FDA Issues Advisory for Increased Risk of Lymphoma in Patients Treated With Golimumab

By

The FDA has issued new warnings on the increased incidence of lymphoma among patients receiving golimumab in clinical trials.

Sign Up for Free e-newsletters